AgomAb Therapeutics NV (AGMB) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oculis is the larger company by market cap ($513.6 million vs $447.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | OCS |
|---|---|---|
| Share price | $9.08 | $8.34 |
| Market cap | $447.17M | $513.64M |
| 1-day change | -1.52% | -3.70% |
| YTD return | — | -58.24% |
| 1-year return | — | -60.53% |
| 5-year return | — | -15.07% |
| EPS (TTM) | $-2.08 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $34.48 |
| 52-week low | $7.97 | $8.30 |
| Distance from 52-week high | -49.05% | -75.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.87% | +340.29% |
| Average volume | 140.06K | 256.38K |
| Shares outstanding | 49.25M | 61.59M |
| Employees | 62 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
AGMB vs OCS FAQ
Which is bigger, AgomAb Therapeutics NV or Oculis?
Oculis (OCS) is larger, with a market capitalization of $513.64M compared with $447.17M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Oculis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for Oculis.